Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event - Annexon Biosciences
	
	
	
	
	
	
	
	
	
	
	
	
	
	
















		
		

 



	

		

			

				
			

		

		                
                

                    

                        

        									

                        								

							

							
clinical pipeline

							
for diseases of the  body, brain & eye

						

        									

                        

											
												

													
													

														
Ben Barres, MD, PhD

														
CO-FOUNDER, ANNEXON, FORMER CHAIR OF NEUROBIOLOGY, STANFORD UNIVERSITY

														
Dr. Barres co-founded Annexon Biosciences and was a Professor and Chair of Neurobiology at Stanford University School of Medicine. He received his BS from Massachusetts Institute of Technology, his MD from Dartmouth Medical School and his PhD at Harvard Medical School in the laboratory of David Corey. Dr. Barres completed his internship and residency in neurology at the Cornell Cooperating Hospitals Program and his postdoctoral fellowship with Martin Raff at University College London. Dr. Barres won many teaching awards at Stanford and was the creator and director of the Masters of Science in Medicine Program, a program at Stanford University designed to train PhD students in human biology and disease. He was a founding member of the Myelin Repair Foundation that focuses on translational research to develop new drugs for multiple sclerosis. Dr. Barres was a Fellow of the American Academy of Arts and Sciences, the National Academy of Sciences and the Institute of Medicine. His laboratory research focused on the role of neuron-glial interactions in the central nervous system.

													

												

											
                    

                

            
    
   

            
            
Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event


            September 20, 2021


            
CAMBRIDGE, Mass., Sept.  20, 2021  (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain and eye, today announced that the company will host its second virtual C1q Series event on Monday, September 27, 2021, at 10:00 a.m. ET, to discuss its neurodegeneration franchise. Annexon’s R&D event will include presentations from the executive team as well as prominent key opinion leaders.


A live webcast and slide presentation will be available in the “Events and Presentations” page of the “Investors” section of annexonbio.com. To register for this event, please access the online registration link here.


About Annexon


Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.


Contacts: 


Investors:
Jennifer Lew
Chief Financial Officer, Annexon Biosciences 
jlew@annexonbio.com


Media:
Miriam Mason 
Annexon Biosciences 
mmason@annexonbio.com




            

« back to news page    

    





	

		

			

				

					

						
Contact Us

						

							info@annexonbio.com

							650.822.5500
						

					

					

						
Annexon, Inc.

						
1400 Sierra Point Parkway, Building C, 
2nd Floor

						Brisbane, CA 94005

					

					

							
							
					

				

				

                    
					
© 2024 Annexon, Inc.  All rights reserved.